SCHEMBL6076547

SCHEMBL6076547

CSSC(O)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.43
ADRA2C P18825 2/20 0.41
KDM4E B2RXH2 2/20 0.41
ADRA2A P08913 1/20 0.41
HIF1A Q16665 1/20 0.41
ALDH1A1 P00352 2/20 0.40
MAPK1 P28482 1/20 0.39
TSHR P16473 2/20 0.39
CHRM2 P08172 1/20 0.39
ADRA1A P35348 1/20 0.39
AOC3 Q16853 1/20 0.39
RGS12 O14924 1/20 0.39
GLA P06280 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
PKM P14618 1/20 0.39
ALOX15 P16050 1/20 0.39
ALOX12 P18054 1/20 0.39
NFKB1 P19838 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22519675 0.80 LMNA (0.46) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL1268813 0.80 LMNA (0.46) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL28106402 0.78 LMNA (0.44) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL10697123 0.75 SLC6A3 (0.41) LMNAADRA2CADRA2ATSHRCYP3A4
SCHEMBL3648024 0.74 ALDH1A1 (0.46) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL15235441 0.73 KMT2A (0.41) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL9633963 0.72 TSHR (0.46) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL1719932 0.70 LMNA (0.42) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL23957711 0.70 TAAR1 (0.39) LMNAADRA2CKDM4EADRA2AHIF1A
SCHEMBL9634660 0.70 RIPK1 (0.44) LMNAADRA2CKDM4EADRA2AHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021216998-A1 MODIFIED NUCLEOTIDES AND USES THEREOF Singular Genomics Systems, Inc. (US) 2021-10-28 WO disclosed
US-7112337-B2 Liposome composition for delivery of nucleic acid ALZA CORPORATION (US) 2006-09-26 US disclosed
US-20030031704-A1 Liposome mixture of a lipid that is neutral in charge at physiologic pH and positively charged at pH values less than physiological pH, and a lipid joined to a hydrophilic polymer by an aromatic disulfide linkage, associated with a nucleic ALZA CORPORATION 2003-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030031704-A1 Liposome mixture of a lipid that is neutral in charge at physiologic pH and positively charged at pH values less than physiological pH, and a lipid joined to a hydrophilic polymer by an aromatic disulfide linkage, associated with a nucleic DLST, LIPA, DNAJC10 LMNA 270/4885ADRA2C 4663/4885KDM4E 3171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.